Archive for the ‘wellness’ tag: Page 14
Feb 24, 2018
Bioquark Inc. — The Mind’s Eye Podcast — Ira Pastor
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, biotech/medical, cryonics, DNA, futurism, genetics, health, life extension
Feb 23, 2018
Bioquark Inc. — Good Men Project — Ira Pastor
Posted by Ira S. Pastor in categories: aging, bioengineering, biotech/medical, DNA, genetics, health, life extension, neuroscience, science, transhumanism
Feb 9, 2018
Bioquark Inc. — Reader’s Digest — Signs Your Body Is Aging Faster Than You Are
Posted by Ira S. Pastor in categories: aging, biological, biotech/medical, business, chemistry, DNA, futurism, genetics, health, innovation
Feb 9, 2018
Bioquark Inc. — Transform U! Show — Ira S. Pastor
Posted by Ira S. Pastor in categories: aging, bioengineering, business, cryonics, DNA, futurism, genetics, health, neuroscience, transhumanism
Jan 15, 2018
Bioquark Inc. — Dr. Gayle Carson / Living Regret Free — Ira Pastor
Posted by Ira S. Pastor in categories: aging, biotech/medical, cryonics, DNA, futurism, genetics, health, life extension, neuroscience, science
Jan 11, 2018
Playboy — DNA To Find The One — Bioquark Commentary
Posted by Ira S. Pastor in categories: biological, biotech/medical, business, DNA, finance, genetics, health, philosophy, science, sex
Jan 9, 2018
Bioquark Inc. — Ira Pastor — Humans 2.0 Podcast
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, business, cryonics, DNA, health, life extension, singularity, transhumanism
Jun 29, 2017
Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Posted by Ira S. Pastor in categories: aging, bioengineering, biotech/medical, disruptive technology, DNA, genetics, health, life extension, posthumanism, science
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
Feb 22, 2017
Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control
Posted by Ira S. Pastor in categories: bioengineering, biotech/medical, business, disruptive technology, DNA, genetics, health, science, sex
Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.
“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”
